Skip to content
  • News
  • Compare
  • Capital
variis
  • Clinics
  • Companies
  • Protocols
  • Specialists
  • Events
  • Funds
  • Press
variis

Longevity intelligence for Singapore and Australia. Sourced and evidence-graded.

Directories

  • Clinics
  • Companies
  • Protocols
  • Specialists
  • Funds
  • Events

Read

  • Archive
  • Capital
  • Compare
  • Glossary

Markets

  • Singapore
  • Australia

variis

  • About
  • Editorial standards
  • AI transparency
  • Corrections
  • Press

Legal

  • Medical disclaimer
  • Privacy policy
  • Terms of service

AI-assisted reporting, human-reviewed. Every claim sourced and graded. Not medical advice.

© 2026 variis · Singapore · Australia

  1. Home
  2. Companies
  3. Clarity Pharmaceuticals Ltd

Company

Clarity Pharmaceuticals Ltd

ASX:CU6

Clinical-stage radiopharmaceutical company. Its SAR Technology platform pairs copper-64 (imaging) and copper-67 (therapy) with the same targeting molecule, so a single agent can both find and treat a tumour. Three candidates: SAR-bisPSMA (prostate cancer, lead), SAR-Bombesin (prostate and other PSMA-negative tumours) and SARTATE (neuroendocrine tumours). Relevance to the variis universe is late-life cancer detection and treatment: prostate and neuroendocrine cancers are strongly age-associated, and the company's clinical case rests on detecting recurrent disease at low PSA levels, i.e. earlier than standard-of-care imaging. Nothing in the pipeline targets ageing biology directly. Qualifies on limbs (a) and (b): ASX-listed and Australian-headquartered. Note it is pre-revenue and pre-approval; no product has regulatory approval.

At a glance

Listing
ASX:CU6
Category
Diagnostics
Headquarters
Eveleigh, Sydney, NSW, Australia
Market cap
~A$866m (17 July 2026, stockanalysis.com; share price A$2.32)

Thesis

Why it is in this universe

Category
Diagnostics
Market
Australia
Recent inflection
14 October 2025: Clarity announced the investigator-initiated Phase II Co-PSMA trial met its primary endpoint, with 64Cu-SAR-bisPSMA PET/CT detecting significantly more lesions per patient than standard-of-care 68Ga-PSMA-11 PET/CT in 50 post-prostatectomy patients with low PSA (company announcement, claritypharmaceuticals.com). This was followed on 14 April 2026 by a commercial manufacturing agreement with Nucleus RadioPharma for 64Cu-SAR-bisPSMA.
Services
None recorded
People tracked
2

Market data

Listing and scale

MetricDetail
ExchangeASX
TickerASX:CU6
Secondary listingNone
Market cap~A$866m (17 July 2026, stockanalysis.com; share price A$2.32)
StatusListed and trading
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.

Get in touch

Contact

Address
Eveleigh, Sydney, NSW, Australia
Website
www.claritypharmaceuticals.com
Phone
No public number published
Email
No public address published

Offering

What it sells today

No commercial services are recorded for this company yet.

People

Who variis tracks here (2)

variis does not publish portraits of named individuals without a licence to do so.

  • JFDr Joel FooATA MedicalAs published on his own clinic bio: family physician with stated interests in men's health and obesity management. This is a self-published area of practice, not a register-confirmed specialist accreditation.MBBS (Singapore), MRCS (Ed), DWD (CAW), GDFM. Also published: Registered Family Physician (FPAB), Basic Obesity Management Accreditation (BOMA), POMS certified, Designated Workplace Doctor (CAW), accredited Lasting Power of Attorney issuer (OPG).Registration published, unchecked
  • LLDr Leonard LengATA MedicalFamily Physician. Published stated interests: Lifestyle Medicine, Longevity Medicine, Obesity Management. No SMC-register specialist accreditation was confirmed.MBBS (NUS), MMed (Family Medicine, NUS), GDOM (Graduate Diploma in Occupational Medicine, NUS), DWD (Designated Workplace Doctor), Registered Family Physician (FPAB), Board Certified in Lifestyle Medicine (American College of Lifestyle Medicine). As published on his clinic bio pages.Registration published, unchecked

Recent inflection

What moved lately

14 October 2025: Clarity announced the investigator-initiated Phase II Co-PSMA trial met its primary endpoint, with 64Cu-SAR-bisPSMA PET/CT detecting significantly more lesions per patient than standard-of-care 68Ga-PSMA-11 PET/CT in 50 post-prostatectomy patients with low PSA (company announcement, claritypharmaceuticals.com). This was followed on 14 April 2026 by a commercial manufacturing agreement with Nucleus RadioPharma for 64Cu-SAR-bisPSMA.

Common questions

Why does variis track Clarity Pharmaceuticals Ltd?
Clinical-stage radiopharmaceutical company. Its SAR Technology platform pairs copper-64 (imaging) and copper-67 (therapy) with the same targeting molecule, so a single agent can both find and treat a tumour. Three candidates: SAR-bisPSMA (prostate cancer, lead), SAR-Bombesin (prostate and other PSMA-negative tumours) and SARTATE (neuroendocrine tumours). Relevance to the variis universe is late-life cancer detection and treatment: prostate and neuroendocrine cancers are strongly age-associated, and the company's clinical case rests on detecting recurrent disease at low PSA levels, i.e. earlier than standard-of-care imaging. Nothing in the pipeline targets ageing biology directly. Qualifies on limbs (a) and (b): ASX-listed and Australian-headquartered. Note it is pre-revenue and pre-approval; no product has regulatory approval.
Is Clarity Pharmaceuticals Ltd publicly listed?
Yes. It trades as ASX:ASX:CU6. Market capitalisation is in the ~A$866m (17 July 2026, stockanalysis.com; share price A$2.32) range, recorded as a dated snapshot rather than a live quote.
Where is Clarity Pharmaceuticals Ltd based?
Eveleigh, Sydney, NSW, Australia
Is Clarity Pharmaceuticals Ltd still trading?
Clarity Pharmaceuticals Ltd is recorded as actively trading.

Keep reading

Related coverage from the newsroom.

Singapore and Australia · Capital

Singapore and Australia · Capital

Two rounds, one IPO: how Singapore and Australia are funding longevity in 2025 to 2026

Suggest an update

Sources

What this profile is built on

  1. Clarity Pharmaceuticals: Radiopharmaceutical Therapies and Imaging (HQ address and SAR Technology pipeline) · Clarity Pharmaceuticals
  2. Clarity Pharmaceuticals Ltd (ASX:CU6) Market Cap · StockAnalysis
  3. Co-PSMA trial achieves primary endpoint · Clarity Pharmaceuticals
  4. Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma · PR Newswire

Last updated 14 August 2026

Every entity profile on variis is sourced. Not investment advice.